HR
TVTX icon

Howe & Rusling’s Travere Therapeutics TVTX Stock Holding History

Howe & Rusling’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-84
Closed -$2K – 1021
2021
Q1 		$2K Buy
84
+18
+27% +$497 ﹤0.01% 851
2020
Q4 		$2K Hold
66
– – ﹤0.01% 837
2020
Q3 		$1K Hold
66
– – ﹤0.01% 801
2020
Q2 		$1K Buy
+66
New +$1.05K ﹤0.01% 773

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Howe & Rusling's TVTX Position: Q2 2021 in Review

Howe & Rusling sold out of Travere Therapeutics (TVTX) in Q2 2021, closing a stake of 84 shares — an estimated $2K sold.

Howe & Rusling first reported a position in TVTX in Q2 2020 and held it in 4 quarters. The position peaked at $2K in Q1 2021. 136 funds tracked by Wall St. Rank hold TVTX as of Q2 2021.

  • Howe & Rusling reported no remaining Travere Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Howe & Rusling sold 84 Travere Therapeutics shares in Q2 2021, an estimated $2K.
  • Howe & Rusling first reported a position in Travere Therapeutics in Q2 2020 and held it in 4 quarters.
  • Howe & Rusling's Travere Therapeutics position peaked at $2K in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2021.

Based on Howe & Rusling's 13F filing for Q2 2021, filed 13 Aug 2021.